Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 5-year average of 0.61%, near the low end of its 5-year range (0.00%–13.16%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 4.76%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
4.76%
DEBT TO ASSETS RATIO AVG 3Y
3.46%
DEBT TO ASSETS RATIO AVG 5Y
0.61%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11%
median of 522 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Damora Therapeutics, Inc.
Market Cap
$1.24B
Debt to Assets Ratio
0.00%
TTM Avg
4.76%
3Y Avg
3.46%
5Y Avg
0.61%
Market Cap
$1.23B
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.20B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.16B
Debt to Assets Ratio
0.23%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.15B
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.15B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.33B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.24B | 0.00% | 4.76% | 3.46% | 0.61% |
| Innovage Holding Corp. (INNV)vs › | $1.23B | 0.16% | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.22B | 0.00% | N/A | N/A | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | 0.04% | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 0.23% | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.15B | 0.07% | N/A | N/A | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.15B | 0.00% | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | 0.00% | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.14B | 0.72% | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.34B | 0.02% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
19.73
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.25% |
| 2025-12-31 | 0.03% |
| 2025-09-30 | 13.16% |
| 2025-06-30 | 10.34% |
| 2025-03-31 | 9.33% |
| 2024-12-31 | 8.36% |
| 2024-09-30 | 0.14% |
| 2024-06-30 | 0.28% |
| 2024-03-31 | 0.48% |
| 2023-12-31 | 0.65% |
| 2023-09-30 | 0.93% |
| 2023-06-30 | 1.06% |
| 2023-03-31 | 1.06% |
| 2022-12-31 | 1.10% |
| 2022-09-30 | 1.05% |
| 2022-06-30 | 0.62% |
| 2022-03-31 | 0.67% |
| 2021-12-31 | 0.69% |
| 2021-09-30 | 0.69% |
| 2021-06-30 | 0.74% |
| 2021-03-31 | 0.60% |
| 2020-12-31 | 0.53% |
| 2020-09-30 | 0.92% |
